
UB563
TargetsPD1-IL2
IndicationsSolid tumour
ClinicalCN - Pre-IND
TherapeuticsOncology
ModalitiesFusion Protein
Asset Materials

How can we help you?
Receive insights into the latest events and regulatory updates
Sent directly to your email
Get industry insights and Unibest news here
Contact Us →